报价延迟最少15分钟:2026/03/09 23:28 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
188.24 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
8.79/15.77
|
|
企业价值
33.71B
|
| 资产负债 |
|
每股账面净值
124.40
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
9.89B
|
|
每股收益
68.09
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis). |
